Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors. - Wikidata - awgldk - TriplyDB

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

http://www.wikidata.org/entity/Q38953705

about

The role of the ALK receptor in cancer biology Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro The role of anaplastic lymphoma kinase in pediatric cancers.CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells.ALK in Neuroblastoma: Biological and Therapeutic Implications.

P2860

Q26738384-60C136ED-5F2B-40A0-B16E-C10CC3125397 Q27853373-962180C9-292A-4472-8F44-29C832404EA3 Q37305906-027194D4-419B-4DED-9F84-D5AD6E0D2566 Q38625880-54CD1B1D-96AB-45EF-B92D-C760DE98B180 Q38700613-972D8A3A-36AD-4821-8BF6-24EAE3ED0376 Q38730798-BEDCF3F9-94CC-410B-8E83-E77DA1886728 Q41844175-F726588B-544F-46E8-BA6D-CCE477C6C3FB Q42227825-8E7CB42C-8613-4F4E-B2C6-3C3E6412BCD0 Q52324760-5E9F4A78-314F-43FE-93B7-F9FD1A3D3752

P2860

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

http://www.wikidata.org/entity/Q38953705

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Intragenic anaplastic lymphoma ...... ation in neuroblastoma tumors.

@en

type

label

Intragenic anaplastic lymphoma ...... ation in neuroblastoma tumors.

@en

prefLabel

Intragenic anaplastic lymphoma ...... ation in neuroblastoma tumors.

@en

P1433

Q38953705-7D0BC174-DEF2-4752-89E7-65721C3D610A

P1476

Q38953705-16A5A159-5C61-44A4-8579-3CF8C626A6DC

P2093

Q38953705-050FD779-E2EE-4253-A129-908C8EF68F3B

Q38953705-2DA29FA1-F7A5-47E6-813D-DC778F1C8210

Q38953705-36290BFF-8960-49C9-84BC-C8D431DE106A

Q38953705-A46E40FF-ACB6-4A38-A160-216E9F4D77A3

Q38953705-CE2744B5-6EC2-4F6D-85A4-42F4B82335DA

Q38953705-EB6FA287-A21B-4DBE-BA9E-CB1AADF7F7BF

P2860

Q38953705-0B9AD99B-A540-47CE-AAC2-D8C172D6CB1B

Q38953705-218814E1-0F0A-474D-B7A4-EA2648EBF477

Q38953705-253787A9-B789-4435-BBCB-28F4A7551CA0

Q38953705-33407C83-4923-48BF-9D15-6A2486690E51

Q38953705-3700A42F-24BD-49FE-B422-8C3114642585

Q38953705-4B89CAE6-329B-4B73-B0EC-034079D494BC

Q38953705-52A9479A-04BA-488D-A215-83970B302E31

Q38953705-5CA7DBAC-6A5C-4D00-B8F0-295483C8BA05

Q38953705-808DD6E0-22C5-4B87-9631-037A1C29FD2A

Q38953705-81EF87E9-5345-4178-A73D-6343EEB9CF21

P304

Q38953705-31B77F0D-BD1D-4DCF-9C42-A1C9B3A204A1

P31

Q38953705-D6E72927-15F5-4FD9-BCC2-D21145D16166

P356

Q38953705-B3459692-EBF7-4099-A786-7B9DD8FB71CF

P433

Q38953705-C575346D-4BD0-4BA6-90CA-67B8971F1421

P478

Q38953705-91DE38B6-0177-4BD5-A349-D3A7D4A75883

P50

Q38953705-0D76530E-9199-4050-833F-B868731A69A7

Q38953705-258ED895-D751-4CB5-9704-D4DE828BCA29

Q38953705-29FA8A3F-F1AA-4E66-AFA4-89E2B6FD95AE

Q38953705-41852CA1-65BF-4D0A-A47C-2DC1A9A25AA9

Q38953705-5795C142-4ECA-4D14-9927-023087DE3471

Q38953705-68A6F900-A014-449D-9B86-E795F3E57206

P577

Q38953705-C970D0E1-5F98-460B-9F78-8B1D883CC121

P5875

Q38953705-89340F3F-5204-4E84-B91A-F17EFC20844D

P698

Q38953705-CF6B305F-FABC-4F03-B0C9-F0ACD1497B92

P356

P1433

Genes, Chromosomes and Cancer

P1476

Intragenic anaplastic lymphoma ...... vation in neuroblastoma tumors

@en

P2093

Ana Berbegall

http://www.w3.org/2001/XMLSchema#string

Anna Djos

http://www.w3.org/2001/XMLSchema#string

Kristina Ruuth

http://www.w3.org/2001/XMLSchema#string

Magnus Hansson

http://www.w3.org/2001/XMLSchema#string

Niloufar Javanmardi

http://www.w3.org/2001/XMLSchema#string

Rosa Noguera

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of ALK as a major familial neuroblastoma predisposition gene

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

ALK and NSCLC: Targeted therapy with ALK inhibitors

Integrative genomics viewer

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.

2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

P304

99-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GCC.22223

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Tommy Martinsson

Jonas Abrahamsson

Susanne Fransson

P577

2014-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266083151

http://www.w3.org/2001/XMLSchema#string

P698

25251827

http://www.w3.org/2001/XMLSchema#string